Bone pain breakthrough? trial tests skipping G-CSF during chemo
NCT ID NCT05753618
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether women with early-stage breast cancer can safely skip a drug called G-CSF during part of their chemotherapy to reduce bone pain. About 242 participants will either receive or skip G-CSF after paclitaxel infusions. The main goal is to see if skipping it lowers pain without causing serious infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Granulocyte colony-stimulating factor (G-CSF) (filgrastim or pegfilgrastim)
What this could lead to
If successful, this could show that many patients can safely skip G-CSF during paclitaxel chemo, reducing bone pain and simplifying treatment.
What could go wrong
This is a small, early-phase trial focused on pain, not on infection rates or cancer outcomes. Skipping G-CSF might increase the risk of febrile neutropenia in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kingston Health Sciences Centre
RECRUITINGKingston, Ontario, K7L 2V7, Canada
-
Lakeridge Health
RECRUITINGOshawa, Ontario, L1G 2B9, Canada
-
The Ottawa Hospital Cancer Centre
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••